CDKN2A and Huntington disease: Currently, CDKN2A HD can usually be evaluated using molecular methods such as fluorescence in situ hybridization (FISH), comparative genomic hybridization, multiplex ligation-dependent probe amplification, next-generation sequencing, or DNA methylation-based profiling.